Abstract
AbstractAdenoid cystic carcinoma (AdCC) is a slow-growing salivary gland malignancy that relapses frequently. AdCCs of the submandibular gland exhibit unique differences in prognosis and treatment response to adjuvant radiotherapy compared to other sites, yet the role of tumor anatomic subsite on gene expression and tumor immune microenvironment (TIME) composition remains unclear. We used 87 samples, including 48 samples (27 AdCC and 21 normal salivary gland tissue samples) from 4 publicly available AdCC RNA sequencing datasets, a validation set of 33 minor gland AdCCs, and 39 samples from an in-house cohort (30 AdCC and 9 normal salivary gland samples). RNA sequencing data were used for single sample gene set enrichment analysis and TIME deconvolution. Quantitative PCR and multiplex immunofluorescence were performed on the in-house cohort. Wilcoxon rank-sum, nonparametric equality-of-medians tests and linear regression models were used to evaluate tumor subsite differences. AdCCs of different anatomic subsites including parotid, submandibular, sublingual, and minor salivary glands differed with respect to expression of several key tumorigenic pathways. Among the three major salivary glands, the reactive oxygen species (ROS)/nuclear factor erythroid 2-related factor 2 (NRF2) pathway signature was significantly underexpressed in AdCC of submandibular compared to parotid and sublingual glands while this association was not observed among normal glands. Additionally, the NRF2 pathway, whose expression was associated with favorable overall survival, was overexpressed in AdCCs of parotid gland compared to minor and submandibular glands. The TIME deconvolution identified differences in CD4+ T cell populations between AdCC of major and minor glands and natural killer (NK) cells among AdCC of minor, submandibular, and parotid glands while plasma cells were enriched in normal submandibular glands compared to other normal gland controls. Our data reveal key molecular differences in AdCC of different anatomic subsites. The ROS and NRF2 pathways are underexpressed in submandibular and minor AdCCs compared to parotid gland AdCCs, and NRF2 pathway expression is associated with favorable overall survival. The CD4+ T, NK, and plasma cell populations also vary by tumor subsites, suggesting that the observed submandibular AdCC tumor-intrinsic pathway differences may be responsible for influencing the TIME composition and survival differences.
Funder
Adenoid Cystic Carcinoma Research Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research
Moffitt Cancer Center
Publisher
Springer Science and Business Media LLC
Reference79 articles.
1. El-Naggar, A. K. C. J., Grandis, J. R., Takata, T. & Slootweg, P. J. WHO Classification of Head and Neck Tumours 4th edn. (IARC Press, 2016).
2. Eveson, D. R., Henley, J. D. & Simpson, R. H. W. Diagnostic Surgical Pathology of the Head and Neck E-Book (Elsevier Health Sciences, 2009).
3. NCCN. Head and neck cancers, version 1.2019. In National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Head and Neck Cancers (version 2.2019). (2019) https://www.ncbi.nlm.nih.gov/pubmed/23946171.
4. Laurie, S. A. et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review. Lancet Oncol. 12, 815–824 (2011).
5. Sogono, P. G., Mejia, M. B. A. & Agas, R. A. F. Addition of concurrent chemotherapy to adjuvant radiotherapy versus radiotherapy alone for resected salivary gland cancers: A systematic review and meta-analysis. J. Clin. Oncol. 35, e17563 (2017).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献